Neoparin Multi (Enoxaparin Sodium)

Neoparin Multi, a low molecular weight heparin, is employed in the prevention and treatment of venous thromboembolism.

• Surgical patients at risk of deep vein thrombosis (DVT): prevents clot formation during and after surgery.
• Patients with acute DVT: facilitates clot resolution and reduces propagation.
• Individuals with pulmonary embolism (PE): treats existing emboli and lowers recurrence risk.
• Medically ill hospitalized patients: provides prophylaxis against thromboembolic events.

• Enoxaparin Sodium binds to antithrombin III, accelerating its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This selective blockade reduces thrombin generation and fibrin clot formation while preserving a degree of platelet function, resulting in effective anticoagulation with a predictable pharmacokinetic profile. The drug’s low molecular weight confers a longer half‑life and allows once‑ or twice‑daily dosing without routine laboratory monitoring in most patients.

Adverse reactions to Enoxaparin Sodium may vary in frequency and severity.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the administration site.
• Minor bleeding or bruising: occasional superficial hemorrhage.
• Nausea or headache: transient gastrointestinal or neurologic symptoms.

Serious or Rare Side Effects

• Major bleeding: life‑threatening hemorrhage requiring medical intervention.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clotting.
• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Spinal or epidural hematoma: bleeding in the central nervous system after neuraxial procedures.
• Severe skin necrosis: localized tissue death at injection sites.
• Paradoxical thrombosis: clot formation despite anticoagulation.

When using Enoxaparin Sodium, clinicians should consider several safety measures.

• Renal impairment: adjust dose or monitor anti‑Xa levels closely.
• Elderly patients: increased bleeding risk; use the lowest effective dose.
• Concurrent anticoagulants: avoid unless clinically justified to prevent additive effects.
• History of HIT: contraindicated due to risk of severe thrombocytopenia.
• Surgery or invasive procedures: discontinue prior to the procedure as recommended.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Enoxaparin Sodium can interact with other medicines, altering its anticoagulant effect.

Major Interactions (Avoid)

• Concurrent use with unfractionated heparin: additive anticoagulant effect, high bleeding risk.
• Combination with warfarin during initial therapy: increased INR and bleeding.
• Use with potent antiplatelet agents (e.g., clopidogrel, high‑dose aspirin): severe hemorrhage.
• Concomitant thrombolytics (e.g., alteplase): excessive bleeding.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding.
• Selective serotonin reuptake inhibitors (SSRIs): modestly raise bleeding tendency.
• Renal‑clearing drugs (e.g., aminoglycosides): may affect drug clearance.
• Contrast media used in imaging: monitor coagulation parameters.